Epitope mapping via selection of anti-FVIII antibody-specific phagepresented peptide ligands that mimic the antibody binding sites

Thrombosis and Haemostasis

Volumn 113, Issue 2, 2015, Pages 396-405

  Kahle, Joerg ^a   Orlowski, Aleksander ^a   Stichel, Diana ^a   Becker Peters, Karin ^a   Kabiri, Ali ^a   Healey, John F ^b   Brettschneider, Kerstin ^a   Naumann, Anja ^a   Scherger, Anna Katharina ^a   Lollar, Pete ^b   Schwabe, Dirk ^a   Königs, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti FVIII antibodies; Epitope mapping; Haemophilia A; Inhibitors; Phage display

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; LIGAND; MONOCLONAL ANTIBODY; BLOOD CLOTTING FACTOR 8; EPITOPE; PEPTIDE; PEPTIDE LIBRARY; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ARTICLE; BACTERIOPHAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GENE MUTATION; HEMOPHILIA A; HUMAN; MOLECULAR CLONING; MUTAGENESIS; MUTATIONAL ANALYSIS; PEPTIDE LIBRARY; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; TRANSIENT EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; HEK293 CELL LINE; IMMUNE SYSTEM; IMMUNOLOGY; MOLECULAR GENETICS; PIG; PROCEDURES; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES, ANTIBODY; EPITOPE MAPPING; EPITOPES; FACTOR VIII; HEK293 CELLS; HEMOPHILIA A; HUMANS; IMMUNE SYSTEM; LIGANDS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; SEQUENCE HOMOLOGY, AMINO ACID; SWINE;

EID: 84922438936     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-01-0101     Document Type: Article

References (27)

1. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-1779.
2. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
3. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' 'bonn protocol'. Vox Sang 1996; 70 (Suppl 1): 30-35.
4. Dimichele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009; 15: 320-328.
5. Hay CR, DiMichele DM, International Immune Tolerance S. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-1344.
6. Greninger DA, Saint-Remy JM, Jacquemin M, et al. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2008; 14: 295-302.
7. van Helden PM, Kaijen PH, Mauser-Bunschoten EP, et al. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A. Haemophilia 2010; 16: 892-901.
8. Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-1480.
9. Prescott R, Nakai H, Saenko EL, et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89: 3663-3671.
10. Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost 2004; 2: 1082-1095.
11. Villard S, Piquer D, Raut S, et al. Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. J Biol Chem 2002; 277: 27232-27239.
12. Villard S, Lacroix-Desmazes S, Kieber-Emmons T, et al. Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood 2003; 102: 949-952.
13. Negi SS, Braun W. Automated detection of conformational epitopes using phage display Peptide sequences. Bioinformat Biol Insights 2009; 3: 71-81.
14. Moreau V, Granier C, Villard S, et al. Discontinuous epitope prediction based on mimotope analysis. Bioinformatics 2006; 22: 1088-1095.
15. Spiegel PC, Jr., Jacquemin M, Saint-Remy JM, et al. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001; 98: 13-19.
16. Muhle C, Schulz-Drost S, Khrenov AV, et al. Epitope mapping of polyclonal clotting factor VIII-inhibitory antibodies using phage display. Thromb Haemost 2004; 91: 619-625.
17. Kessel C, Konigs C, Linde R, et al. Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. Mol Immunol 2008; 46: 8-15.
18. Markovitz RC, Healey JF, Parker ET, et al. The diversity of the immune response to the A2 domain of human factor VIII. Blood 2013; 121: 2785-2795.
19. Ngo JC, Huang M, Roth DA, et al. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008; 16: 597-606.
20. Jacquemin MG, Desqueper BG, Benhida A, et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998; 92: 496-506.
21. Gringeri A, Musso R, Mazzucconi MG, et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-379.
22. Van Regenmortel MH. From absolute to exquisite specificity. Reflections on the fuzzy nature of species, specificity and antigenic sites. J Immunol Methods 1998; 216: 37-48.
23. Jin L, Fendly BM, Wells JA. High resolution functional analysis of antibodyantigen interactions. J Mol Biol 1992; 226: 851-865.
24. Nguyen PC, Lewis KB, Ettinger RA, et al. High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance. Blood 2014; 123: 2732-2739.
25. Funk WD, MacGillivray RT, Mason AB, et al. Expression of the amino-terminal half-molecule of human serum transferrin in cultured cells and characterization of the recombinant protein. Biochemistry 1990; 29: 1654-1660.
26. Healey JF, Parker ET, Barrow RT, et al. The humoral response to human factor VIII in hemophilia A mice. J Thromb Haemost 2007; 5: 512-519.
27. Doering C, Parker ET, Healey JF, et al. Expression and characterization of recombinant murine factor VIII. Thromb Haemost 2002; 88: 450-458.